# The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Study · id `cardio:ct-nct02059187` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02059187](<https://clinicaltrials.gov/study/NCT02059187>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02059187

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 531 participants.

## Technical summary

Registry record NCT02059187. Randomized; no masking; primary purpose treatment. Start 2014-02-11 (actual); primary completion 2015-03-11 (actual). Results posted on 2017-03-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 531 participants (enrolled count; ClinicalTrials.gov record NCT02059187, source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)
- Started: 2014-02-11 (actual) (ClinicalTrials.gov record NCT02059187, source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)
- Primary completion: 2015-03-11 (actual) (ClinicalTrials.gov record NCT02059187, source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)
- Completion: 2015-03-11 (actual) (ClinicalTrials.gov record NCT02059187, source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)
- Results first posted: 2017-03-08 (ClinicalTrials.gov record NCT02059187, source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02059187-2018-09-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): MK-1293
- Intervention (Drug): Lantus™
- Intervention (Drug): Prandial insulin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial (`cardio:pubmed-29761615`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 44edb42d512a2ef3ac09ec9582091a1a88db0e9293769a99787cc2ea7e688fba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
